better-than-expect result updat competit landscap
diabet increas estim sale ep growth unchang
industri averag
line ep guidanc previous rais estim
thereaft increas ep estim per year
ep compound-annual-growth-rate unchang
well group averag
line sale guidanc rais estim
thereaft increas sale estim per year
sale compound-annual-growth-rate unchang
group averag
oper margin estim decreas roughli
intact forecast decreas tax
rate estim consist compani guidanc forecast flat tax rate
increas year
competitor diabet held recent confer call and/or meet
landscap discuss length acknowledg increas pressur
price learn new signific concern dynam market sni
launch admelog biosimilar humalog risk novo cite competit
price time tandem long-term contract could blunt biosimilar
uptak despit discount launch way novo ozemp semaglutid
weekli inject novo believ demonstr superior trulic
allow perform well market consult counter clinic
differ ozemp trulic small unlik seen clinic
benefit ozemp lower dose match trulic higher
dose oral semaglutid phase date risk say highli
interest space although believ modal sub-optim small
molecul target receptor would prefer novo counter
difficult replic action agonist small molecul
year lead approach novo agre outlook class
bright expect good growth go forward cowen annual drug price trend
survey suggest diabet becom less focu buyer come price
howev compani will confirm
pleas see page report import disclosur
number promis new drug rollout late-stag agent pois launch
next year give us confid top-tier sale ep growth prospect pipelin
visibl improv overal margin target appear achiev estim
ep compound-annual-growth-rate among best pharma dividend yield attract
baricitinib eu japan rollout
perform diabet busi
galcanezumab approv migrain
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
alimta declin rapidli
margin expans plan delay
margin expans sooner greater
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas
oncolog among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
compani data cowen compani
compani data cowen compani
productstrul europ lc ex europ lc ex europ lc ex europ lc ex world-wide share europ lc ex world-wide share cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
healthfood end market sale euro end market sale world-wide share end market sale euro end market sale world-wide share cowen
compani data cowen compani
growth productstrul us share novo competit manageabletrul europ lc ex fx -australia europetrul eu emerg marketstrul qweek dose type diabet rewind cv studi data studi continu post interim lookforteo expir biosimilar launch new modal anticipatedforteo europ lc ex fx -australia europeforteo expir biosimilar launch anticipatedforteo expir biosimilar launch anticipatedforteo emerg marketsforteo hormon osteoporosi two year durat treatmentcyramza pressur io target agentscyramza europ lc ex fx -australia europecyramza nsclc cyramza uptak gastriccyramza emerg marketscyramza ramu app gastric lung ph bladder lungjardi us empa-reg cv outcom studi reflect label heart failur studi underwayjardi europ lc ex fx -australia europejardi eu empa-reg data file file jardiance/trajenta nda eujardi japanjardi emerg market approv chinajardi world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf studi initiatedtrajenta market share patent expir europ lc ex fx -australia europetrajenta patent expir patent expir emerg marketstrajenta world-wide share inhibitor cv outcom data expect share gross profit bi reflect revenu cowen
compani data cowen compani
new drugstaltz psoriasi market share competit landscap evolv rapidlytaltz europ lc ex fx taltz eu mod/sever psoriasi taltz phase axspabasaglar/abasria settlement w/sni allow launch strong launchbasaglar/abasria europ lc ex fx basaglar/abasria market eubasaglar/abasria countri basaglar/abasria insulin glargin diabet lantu biosimilar expectedglucagon europ lc ex fx gucagon hypoglycemia intranas file expect europ lc ex fx adcirca pulmonari arteri hypertensionlartruvo soft tissu sarcoma europ lc ex fx lartruvo pdgf alpha inhib approv file file eu/japan approv expect inhib ra re-fil launch eu japan atop derm posit bace inib alzheim ph w/azn interim safeti look pass prodrom phase mab file episod chronic migrain cluster ha data file oral human ant-egfr fda approv line squamou nsclc launch eu cowen
compani data cowen compani
new drug sever pain oa pain clbp phase data treatment phase studi posit oral altern deliveri consid via colucid diagnost tau imag agent phase data rapid act phase dm develop inhibitor phase inhibitor small molecul cancer phase ii tier develop clarifi data expect sever phase diseas imag phase amylin calcitonin receptor agonist diabet phase phase ulcer coliti phase iibac diseas phase iibtk phase phase diseas phase iierbitux sale full right close royalti europ lc ex fx -australia europeerbitux royalti report ou revenu key greater transpar drug solderbitux royalti royalti kgaa asset due fulli paid licenseerbitux royalti growth new drug sale drugsalimta exp pedi extens vitamin supplement patent prevail appeal pto deni ipr vitamin supplement patent approv use keytruda nsclcalimta europ lc ex fx -australia europealimta exp vitamin supplement patent til eu upheld defeat germani appeal underway gener launchedalimta exp method-of-us patent eu alimta emerg marketsalimta synthetas inhib mesothelioma nscl io/target agent impact nsclc usageciali expir pedi exclus pend patent litig settlement allow gener launch gener sildenafil pressuringciali europ lc ex fx -australia europeciali expir expir emerg marketsciali bphhumatrop europ lc ex fx -australia europehumatrop emerg marketshumatrop cowen
compani data cowen compani
establish drug continuedeffi expir includ pedi exclus effient europ lc ex fx -australia europeeffi expir emerg marketseffi trilog medic mgd patient accoast pre-tx trigger drug elut stent miss endpointsevista expir multipl gener soldevista europ lc ex fx -australia europeevista expir expir emerg marketsevista breast cancer preventioncymbalta expir multipl gener soldcymbalta europ lc ex fx -australia europecymbalta exclus expir gener launch mid expir emerg marketscymbalta pain gad fibromyalgia chronic painzyprexa expir author gener sale book herezyprexa europ lc ex fx -australia europezyprexa expir expir gener launch emerg marketszyprexa strattera market share patent expir europ lc ex fx -australia canada europestrattera expir emerg marketsstrattera deficit hyperactivityprozac europ lc ex fx -australia europeprozac competitionprozac emerg marketsprozac europ lc ex fx -australia europegemzar emerg marketsgemzar nsclc bladder breast ovarian gener cowen
compani data cowen compani
establish drug continuedreopro europ lc ex fx -australia europereopro emerg marketsreopro mix view competit productsaxiron launchedaxiron europ lc ex fx axiron topic solut agreement acrux market eu pursu chf market foreign sale otcor cd outlicens dura antibiot focusinject inject antibiot market share sni biosimilar rcv approv europ lc ex fx -australia europehumalog biosimilar approv eu emerg marketshumalog act insulin patent expir europ lc ex fx -australia europehumulin emerg marketshumulin patent protectionoth productsinsulin hyperlipidemia kowa latin american right retain right patent expir intern product beirsdorf german drug manuf establish drug drug sale new product cowen
compani data cowen compani
compani data cowen compani
anim healthfood nv acquisit close addit jansen sales/yr lohmann sales/yr sales/yr close option explor includ ipo merger sale retent updat later industri averagey/i trajenta end market sale euro rate end market sale world-wide share inhibitor cv outcom data expect share gross profit bi reflect revenuejardi end market sale euro rate end market sale world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf studi initi cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
